HT
APLS

Headlands Technologies’s Apellis Pharmaceuticals APLS Stock Holding History

Headlands Technologies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,892
Closed -$119K – 637
2025
Q2 		$119K Buy
6,892
+6,080
+749% +$113K 0.01% 591
2025
Q1 		$17.8K Buy
+812
New +$22.4K ﹤0.01% 876
2023
Q3 		– Sell
-5,183
Closed -$472K – 913
2023
Q2 		$472K Buy
+5,183
New +$447K 0.15% 160

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Headlands Technologies's APLS Position: Q3 2025 in Review

Headlands Technologies sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 6,892 shares — an estimated $119K sold.

Headlands Technologies first reported a position in APLS in Q2 2023 and held it in 3 quarters. The position peaked at $472K in Q2 2023. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Headlands Technologies reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 6,892 Apellis Pharmaceuticals shares in Q3 2025, an estimated $119K.
  • Headlands Technologies first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Headlands Technologies's Apellis Pharmaceuticals position peaked at $472K in Q2 2023.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.